UCB enters into collaboration with Roche to develop antibody treatment for people living with Alzheimer’s Disease

Bimekizumab Superior to Cosentyx® in Achieving Complete Psoriasis Skin Clearance

UCB and Ferring Pharmaceuticals Announce Co-Promotion of CIMZIA^® (certolizumab pegol) for the Treatment of Adults with Moderate to Severe Crohn’s Disease

Six poster presentations highlight clinical data on NAYZILAM^® (midazolam) nasal spray CIV and BRIVIACT^® (brivaracetam) CV in addition to epilepsy-related health economics outcomes research

Atlanta, Ga., June 24, 2020: UCB today announced six posters selected for presentation at the 72nd American Academy of Neurology (AAN) annual meeting, available online via the 2020 AAN Science Highlights virtual platform, which replaced the in-person event previously cancelled due to the COVID-19 pandemic. The abstracts were also published in the online supplement to Neurology.

• Data from the Phase 3 BE VIVID and BE READY studies show that bimekizumab-treated patients with psoriasis achieved significant skin clearance at week 16, rapid response after one dose, and durability of response up to a year
• Results support the importance of selectively inhibiting IL-17F, in addition to IL-17A, with bimekizumab

• Underlines UCB’s leadership in epilepsy by adding Staccato^® Alprazolam, a drug-device-combination with the potential to be the first on-demand, single-use treatment to rapidly terminate an active epileptic seizure

UCB completes the acquisition of Ra Pharmaceuticals – to deliver differentiated therapies to patients.

UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting

Bimekizumab Phase 3 Psoriasis Study Demonstrates Superiority Versus Humira®

• 14 scientific presentations will cover UCB’s pipeline assets, epilepsy-specific research, and licensed medicines, including NAYZILAM, now available for the acute treatment of seizure clusters in epilepsy patients 12 years of age and older
• Friday evening symposium on “Epilepsy Treatment Update for Patients Suffering from Seizure Clusters” includes Epilepsy Foundation’s project on seizure emergencies and a panel discussion on the misconceptions around seizure clusters